Novartis: FDA accepts filing for new AMD drug
(CercleFinance.com) - Novartis said that the US Food and Drug Administration had accepted for review the filing of a new drug application for a new wet age-related macular degeneration drug.
The FDA has accepted the company's biologics license application for brolucizumab for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD.
Novartis used a priority review voucher to expedite the FDA review.
If approved by the FDA, Novartis expects to launch the product by the end of 2019, it said.
AMD is the leading cause of blindness in industrialised countries.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA has accepted the company's biologics license application for brolucizumab for the treatment of wet age-related macular degeneration (AMD), also known as neovascular AMD, or nAMD.
Novartis used a priority review voucher to expedite the FDA review.
If approved by the FDA, Novartis expects to launch the product by the end of 2019, it said.
AMD is the leading cause of blindness in industrialised countries.
Copyright (c) 2019 CercleFinance.com. All rights reserved.